0.00%
-3.14%
-12.39%
-29.09%
-28.45%
-14.48%
-4.97%
AI Spotlight on GXI
Company Description
Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide.It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions.The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements.
The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; miniature bottles and glass containers for liquid food, spices, and spirits; and packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products.The Advanced Technologies division develops smart drug delivery systems, such as micro pumps, which are used to self-administer medication for Parkinson's disease or heart failure to pharmaceutical and biotech customers.The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
Market Data
| Last Price | 67.9 |
| Change Percentage | 0.00% |
| Open | 67.85 |
| Previous Close | 67.9 |
| Market Cap ( Millions) | 2345 |
| Volume | 135762 |
| Year High | 111.2 |
| Year Low | 62.9 |
| M A 50 | 71.15 |
| M A 200 | 88.8 |
Financial Ratios
| FCF Yield | -5.15% |
| Dividend Yield | 1.84% |
| ROE | 7.89% |
| Debt / Equity | 87.94% |
| Net Debt / EBIDTA | 290.34% |
| Price To Book | 1.64 |
| Price Earnings Ratio | 20.52 |
| Price To FCF | -19.43 |
| Price To sales | 1.17 |
| EV / EBITDA | 8.82 |
News
- Jan -28 - Three Stocks That May Be Priced Below Their Estimated Value In January 2025
- Jan -21 - Is Gerresheimer AG (ETR:GXI) Trading At A 43% Discount?
- Dec -27 - 3 Stocks Estimated To Be Up To 47.5% Below Intrinsic Value
- Dec -03 - Gerresheimer invests €100m in Skopje facility for syringe production
- Nov -25 - 3 Stocks Estimated To Be Trading Below Fair Value By Up To 50%
- Nov -07 - Why Gerresheimer AG (ETR:GXI) Could Be Worth Watching
- Oct -22 - 3 German Stocks Estimated To Be Up To 45.2% Below Intrinsic Value
- Oct -15 - Gerresheimer expands green electricity supply at Belgium site
- Oct -13 - Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
- Oct -09 - Gerresheimer AG (GRRMY) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Challenges
- Oct -05 - Gerresheimer Third Quarter 2024 Earnings: Misses Expectations
- Oct -01 - Gerresheimer sees 1.5% revenue growth in 9M FY24
- Sep -26 - Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry "Alliance for RTU"
- Sep -23 - Gerresheimer AG (ETR:GXI) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?
- Sep -05 - adidas And 2 More German Stocks That Could Be Trading Below Their Estimated Value
- Aug -14 - Are Investors Undervaluing Gerresheimer AG (ETR:GXI) By 49%?
- Jul -29 - Exploring Three German Exchange Stocks With Intrinsic Discounts Ranging From 22.3% To 33.7%
- Jul -14 - Gerresheimer AG Just Missed Earnings - But Analysts Have Updated Their Models
- Jul -12 - Exploring Undervalued Opportunities On The German Exchange With Discounts Ranging From 12.8% To 33.6%
- Jul -11 - Unveiling Three German Exchange Stocks Believed To Be Trading Below Estimated Fair Values
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Plastics and Devices
Expected Growth : 8 %
What the company do ?
Gerresheimer AG's Plastics and Devices segment produces and sells pharmaceutical packaging, drug delivery devices, and medical devices for the healthcare industry.
Why we expect these perspectives ?
Gerresheimer AG's Plastics and Devices segment growth is driven by increasing demand for high-value devices, such as insulin pens and inhalers, and growing adoption of plastic packaging for pharmaceuticals. Additionally, the company's focus on innovation, expansion into emerging markets, and strategic partnerships contribute to its 8% growth rate.
Segment n°2 -> Primary Packaging Glass
Expected Growth : 9 %
What the company do ?
Primary Packaging Glass from Gerresheimer AG refers to high-quality glass packaging solutions for pharmaceutical, cosmetic, and food industries, ensuring product safety and integrity.
Why we expect these perspectives ?
Strong demand for sustainable and premium packaging, increasing adoption of glass packaging in the pharma and cosmetics industries, and Gerresheimer's strategic expansion into emerging markets drive the 9% growth of Primary Packaging Glass. Additionally, the company's focus on innovation, quality, and customer relationships further supports this growth.
Segment n°3 -> Advanced Technologies
Expected Growth : 11 %
What the company do ?
Gerresheimer AG's Advanced Technologies segment offers innovative solutions for pharmaceutical and medical devices, including inhalers, insulin pens, and other drug delivery systems.
Why we expect these perspectives ?
Gerresheimer AG's Advanced Technologies segment growth is driven by increasing demand for innovative medical devices, rising adoption of digital healthcare solutions, and growing need for pharmaceutical packaging and drug delivery systems. Additionally, strategic partnerships, investments in R&D, and expansion into emerging markets contribute to the 11% growth.
Gerresheimer Ag Products
| Product Range | What is it ? |
|---|---|
| Pharmaceutical Primary Packaging | Gerresheimer AG offers a wide range of pharmaceutical primary packaging products, including vials, cartridges, and syringes, designed to protect and preserve sensitive pharmaceutical products. |
| Medical Plastic Systems | Gerresheimer AG provides medical plastic systems, including inhalers, insulin pens, and other medical devices, designed for safe and efficient delivery of medications. |
| Moulded Glass | Gerresheimer AG offers moulded glass products, including vials, cartridges, and syringes, designed for pharmaceutical and biotechnological applications. |
| Syringes and Cartridges | Gerresheimer AG provides syringes and cartridges designed for safe and efficient injection of medications, including prefilled syringes and cartridges. |
| Tubular Glass | Gerresheimer AG offers tubular glass products, including ampoules, vials, and cartridges, designed for pharmaceutical and biotechnological applications. |
| Device Technology | Gerresheimer AG provides device technology solutions, including inhalers, insulin pens, and other medical devices, designed for safe and efficient delivery of medications. |
Gerresheimer AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for Gerresheimer AG is medium due to the presence of alternative packaging solutions, but the company's focus on innovative and specialized products reduces the likelihood of substitution.
Bargaining Power Of Customers
The bargaining power of customers is low due to the company's strong relationships with its clients and the customized nature of its products, which reduces the ability of customers to negotiate prices.
Bargaining Power Of Suppliers
The bargaining power of suppliers is medium due to the company's dependence on a few key suppliers for raw materials, but the company's large scale of operations and long-term contracts mitigate this risk.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the pharmaceutical packaging industry, including the need for significant capital investment and regulatory compliance.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of several established players in the pharmaceutical packaging industry, leading to a competitive pricing environment and a focus on innovation and differentiation.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 41.87% |
| Debt Cost | 6.75% |
| Equity Weight | 58.13% |
| Equity Cost | 8.48% |
| WACC | 7.76% |
| Leverage | 72.03% |
Gerresheimer AG : Quality Control
Gerresheimer AG passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| TECN.SW | Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business … |
| YPSN.SW | Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and … |
| AMP.MI | Amplifon S.p.A. retails hearing care products and services that help people rediscover various emotions of sound. The company offers ampli-easy, ampli-mini, ampli-connect, and ampli-energy hearing devices. It also provides fitting … |
| EKTA-B.ST | Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac … |
| AFX.DE | Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Elekta
A-Score
1-Year Total Return ->
🥈
Ypsomed
A-Score
1-Year Total Return ->
🥉
Amplifon
A-Score
1-Year Total Return ->
4
Tecan
A-Score
1-Year Total Return ->
5
Gerresheimer
A-Score
1-Year Total Return ->
6
